Volumetric modulated arc therapy (VMAT)

Series
Radiotherapy
Status
Published
Date
Number of report
030

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for Volumetric modulated arc therapy (VMAT) in European countries.      

The analysis covers the application of VMAT in head and neck cancer, prostate and lung cancer.

The analysis is provided for the session and out-patient treatment, including both preparation and delivery of VMAT. The only reimbursement within public / statutory health insurance systems is considered.

The report includes essential information about reimbursement, including:

  • Brief country-specific overview of reimbursement system
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions on indications or scenarios for the use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • Finland
  • France
  • Germany
  • Italy
  • The Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of equipment for volumetric modulated arc therapy include:

  • Elekta (Infinity)
  • Panacea Medical Technologies (BHABHATRON-II)
  • Varian Medical Systems (Halcyon)

Table of content 

1.    Introduction and summary
2.    Executive summary table
3.    Contents
4.    Abbreviations
5.    Methodology
6.    What’s new
7.    Reimbursement analysis in Austria

7.1.    Overview of the reimbursement system
7.2.    Reimbursement for volumetric modulated arc therapy
7.2.1.    Procedure coding
7.2.2.    Diagnosis coding
7.2.3.    Payment mechanism and reimbursement tariffs
7.2.4.    Health technology assessments by LBI-HTA
8.    Reimbursement analysis in Belgium
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for volumetric modulated arc therapy
8.2.1.    Procedure coding
8.2.2.    Payment mechanism and reimbursement tariffs
8.2.3.    Policy considerations by the INAMI/RIZIV
8.2.3.1.    Health technology assessments by KCE
9.    Reimbursement analysis in Denmark
9.1.    Overview of the proton therapy
9.2.    Reimbursement for volumetric modulated arc therapy
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations
10.    Reimbursement analysis in England
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for volumetric modulated arc therapy
10.2.1.    Procedure coding 
10.2.2.    Payment mechanism and reimbursement tariffs
10.2.3.    Policy considerations 
10.2.3.1.    Specifics of commissioning of the procedure
10.2.3.2.    Health technology assessments by NICE
11.    Reimbursement analysis in Finland
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for volumetric modulated arc therapy
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations
12.    Reimbursement analysis in France
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for volumetric modulated arc therapy
12.2.1.    Procedure coding 
12.2.2.    Diagnosis coding
12.2.3.    Payment mechanism and reimbursement tariffs
12.2.4.    Policy considerations by HAS
13.    Reimbursement analysis in Germany
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for volumetric modulated arc therapy
13.2.1.    Procedure coding 
13.2.2.    Payment mechanism and reimbursement tariffs
13.2.3.    Policy considerations by G-BA
14.    Reimbursement analysis in Italy
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for volumetric modulated arc therapy
14.2.1.    Procedure coding at national level
14.2.2.    Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
14.2.3.    Payment mechanism and reimbursement tariffs at national level
14.2.4.    Payment mechanism and reimbursement tariffs at regional level
14.2.5.    Policy considerations
15.    Reimbursement analysis in the Netherlands
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for volumetric modulated arc therapy
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations by Dutch Healthcare Institute (ZIN)
16.    Reimbursement analysis in Norway
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for volumetric modulated arc therapy
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations 
17.    Reimbursement analysis in Sweden
17.1.    Overview of the reimbursement system
17.2.    Reimbursement for volumetric modulated arc therapy
17.2.1.    Procedure coding 
17.2.2.    Diagnosis coding
17.2.3.    Payment mechanism and reimbursement tariffs
17.2.4.    Policy considerations
18.    Reimbursement analysis in Switzerland
18.1.    Overview of the reimbursement system
18.2.    Reimbursement for volumetric modulated arc therapy
18.2.1.    Procedure coding 
18.2.2.    Payment mechanism and reimbursement tariffs
18.2.3.    Policy considerations
19.    Summary of procedure codes
20.    Summary of reimbursement codes and tariffs
21.    Disclaimer

26

Jul 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.

Read more

05

Jul 2021

On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).

Read more

16

Jun 2021

The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.

Read more

04

Jun 2021

On May 17, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering the period January 20, 2021 - April 20, 2021). One new Clinical Commissioning Policy related to radiotherapy was added to the work program, and four new policies related to radiotherapy were published in the period from January 20, 2021, to April 20, 2021. Two policies related to heart valve procedures and extracorporeal treatment were discontinued.

Read more

09

Mar 2021

On February 24, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering period November 10, 2020 - February 10, 2021). Two new Clinical Commissioning Policies were added to the work program, and seven new policies were published, including stereotactic ablative radiotherapy, stereotactic radiosurgery and proton therapy. The status of ongoing policies was updated as well.

Read more
(we accept only company emails)